https://orcid.org/0000-0003-1672-9560
References
- Curigliano G, O’ Connor DP, Rosenberg JA, et al. Biosimilars: extrapolation for oncology. Crit Rev Oncol Hematol. 2016 Aug;104:131–137.
- WHO. Biologicals: similar biotherapeutic products; 2019. [cited 2019 Oct 13]. Available from: https://www.who.int/biologicals/biotherapeutics/similar_biotherapeutic_products/en/.
- WHO. Report of the WHO Expert Committee on Selection and Use of Essential Medicines; 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). [cited 2019 Nov 17]. Available from: https://www.who.int/medicines/publications/essentialmedicines/UNEDITED_TRS_2019_EC22_Sept.pdf
- von Minckwitz G, Colleoni M, Kolberg HC, et al. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2018;19:987–998.
- Stebbing J, Baranau Y, Baryash V, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 2017;18:917–928.
- Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA. 2017;317:37–47.
- Pegram MD, Bondarenko I, Zorzetto MMC, et al. PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. Br J Cancer. 2019;120:172–182.
- Lammers PE, Dank M, Masetti R, et al. Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. Br J Cancer. 2018;119:266–273.
- Pivot X, Bondarenko I, Nowecki Z, et al. Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol. 2018;36:968–974.
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
- GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet. 2018 Jun 2;391(10136):2236–2271.
- WHO. The global health observatory; 2019. [cited 2019 Nov 17]. Available from: http://apps.who.int/gho/portal/uhc-fp-cabinet-wrapper-v2.jsp?id=1020101
- UN. Sustainable development goals. [cited 2019 Nov 17]. Available from: https:// www.un.org/ sustainabledevelopment/ sustainable-development-goals/.
- Pramesh CS, Chaturvedi H, Reddy VA, et al. Choosing Wisely India: ten low-value or harmful practices that should be avoided in cancer care. Lancet Oncol. 2019 Apr;20(4):e218–e223.
- Jarvis JD, Murphy A, Perel P, et al. Acceptability and feasibility of a national essential medicines list in Canada: a qualitative study of perceptions of decision-makers and policy stakeholders. CMAJ. 2019 Oct 7;191(40):E1093–E1099.